Next Phase Newsletter

The firm is a leading European venture capital firm investing in early- and growth-stage life science companies. The firm focuses on biotechnology, therapeutics, medical technology, diagnostics, digital health, and life science tools. The firm has a long track record of supporting innovative companies as they translate scientific breakthroughs into high-growth businesses. To date, the firm has invested in more than 60 life science companies, including multiple successful acquisitions by large pharmaceutical and medical technology companies. Initial investment sizes typically range from EUR 5–10 million, with the potential to invest up to EUR 20 million over the life of an investment. 

The firm invests primarily in Europe and selectively in the United States across five broad areas: therapeutics, medtech, diagnostics, digital health, and biotechnology and R&D tools. Within therapeutics, the firm focuses on early-stage companies with preclinical proof-of-concept data or programs approaching clinical entry, with a preference for highly innovative technology platforms and opportunities supported by early clinical data. In other sectors, the firm prefers companies with product candidates supported by strong intellectual property that are approaching regulatory approval or companies that have already launched a first product and achieved early market traction. 

From a company and management team perspective, the firm typically seeks a board seat and places strong emphasis on experienced, high-quality management teams. At the same time, the firm actively supports highly talented entrepreneurs and works closely with portfolio companies to help drive strategic, operational, and commercial execution. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm with offices in the U.S. and Europe, with a dual-fund structure, invests across several industries, with one of its focuses in healthtech and medtech. The firm’s sweet spot on early-stage companies, focused on Pre-seed to Series A, with potential follow-on investment in Series B. Typical check sizes range from $ 500K – $ 3M. Geographically, the firm is open to opportunities globally and does not have a preference for leading or co-investing in rounds. 

Within life science and healthcare, the firm is interested in Medical Devices through a 4-Pillar focus: (1) Early detection technologies, (2) Robotics, automation, precision medicine, and minimally invasive devices, (3) Digital health and applications, (4)  Brain–computer interface 

Traditional biotech therapeutics is generally not of interest. The firm is agnostic in terms of indications/disease areas. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A French venture capital firm historically focused on deep-tech and hardware but is now broadening their scope to sectors such as the intersection between deep-tech and life sciences. Currently investing from their second fund of USD $75M, the firm participates in Pre-Seed and Seed rounds, typically allocating between USD $500K – $2.5M. The firm prefers to lead or co-lead and looks at companies in Europe and the U.S. 

In terms of life sciences, the firm is open to digital health deep-tech companies but are not interested in apps. The firm does not look at traditional therapeutics but will look at therapeutics with a data component or multi-asset and platform technologies. The firm is also open to diagnostics, non-invasive medical devices, surgical tools, and biomanufacturing. The firm looks at companies that are in their pre-clinical and development stages. The firm is disease-agnostic. 

The firm may take a board or observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm founded in 2024 and has USD $40M under management seeks to invest in Pre-Seed and Seed stage longevity biotech companies developing technologies that can significantly extend healthy human lifespan and are scalable for everyone. Initial check size ranges between USD $250K – $1.5M with the ability to lead or co-lead. The firm is open to global companies but prefers the US, UK, and EU. 

The firm is open to all technologies, except single assets, that address longevity. Areas of interest include breakthroughs in multiple areas including AI, synthetic biology, stem cell therapies, gene sequencing and editing, protein engineering, tissue engineering, and more. Every company they invest in must have the potential to extend healthy human lifespan by at least 10+ years. Companies of interest are typically still in pre-clinical stages. The firm seeks out companies with a strong ethical foundation and robust scientific backing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology